Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels.
Abstract An elevation of lipoprotein(a) (Lp(a)) is an internationally recognized atherogenic risk factor, documented in epidemiological studies, in studies with Mendelian randomization and in genome-wide association studies (GWAS). At present, no drug is available to effectively reduce its concentration. In Germany, an elevation of Lp(a) associated with progressive cardiovascular diseases is officially recognized as an indication for a lipoprotein apheresis (LA). The number of patients who were treated with LA with this abnormality was steadily increasing in the years 2013-2016 - the official data are reported. In...
Source: Atherosclerosis Supplements - December 1, 2019 Category: Cardiology Authors: Julius U, Tselmin S, Schatz U, Fischer S, Birkenfeld AL, Bornstein SR Tags: Atheroscler Suppl Source Type: research

ADMA elevation does not exacerbate development of diabetic nephropathy in mice with streptozotocin-induced diabetes mellitus.
CONCLUSIONS: In summary, STZ-induced diabetes led to the development of early features of diabetic nephropathy. Deficiency of DDAH1 and subsequent increase in systemic ADMA levels did not exacerbate these changes, indicating that ADMA is not the major mediator of diabetic nephropathy in this experiment model. PMID: 31818438 [PubMed - in process] (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - December 1, 2019 Category: Cardiology Authors: Rodionov RN, Jarzebska N, Schneider A, Rexin A, Sradnick J, Brilloff S, Martens-Lobenhoffer J, Bode-Böger SM, Todorov V, Hugo C, Weiss N, Hohenstein B Tags: Atheroscler Suppl Source Type: research

Kidney and liver are the main organs of expression of a key metabolic enzyme alanine:glyoxylate aminotransferase 2 in humans.
CONCLUSIONS: Our current data suggest that both hepatocytes and kidney tubular epithelial cells are the major sources of AGXT2 in humans. We also demonstrated the mitochondrial localization of human AGXT2 enzyme. PMID: 31818439 [PubMed - in process] (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - December 1, 2019 Category: Cardiology Authors: Jarzebska N, Georgi S, Jabs N, Brilloff S, Maas R, Rodionov RN, Zietz C, Montresor S, Hohenstein B, Weiss N Tags: Atheroscler Suppl Source Type: research

A complicated pregnancy in homozygous familial hypercholesterolaemia treated with lipoprotein apheresis: A case report.
CONCLUSIONS: LA is a safe and effective tool in HoFH subjects even in pregnancy. Evidence based guidelines for the management of these patients during pregnancy are still lacking. PMID: 31818440 [PubMed - in process] (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - December 1, 2019 Category: Cardiology Authors: Perrone S, Perrone G, Brunelli R, Di Giacomo S, Galoppi P, Flammini G, Morozzi C, Stefanutti C Tags: Atheroscler Suppl Source Type: research

A successful term pregnancy with severe hypertriglyceridaemia and acute pancreatitis. Clinical management and review of the literature.
CONCLUSIONS: PEX led to a positive maternal outcome in absence of foetal and gestational complications in a case of severe HP in pregnancy. As clinical trials are lacking, case reports still represent the best way to reasonably implement clinical management of this rare but life-threatening disease. PMID: 31818441 [PubMed - in process] (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - December 1, 2019 Category: Cardiology Authors: Perrone S, Brunelli R, Perrone G, Zannini I, Galoppi P, Di Giacomo S, Morozzi C, Pisciotta L, Stefanutti C Tags: Atheroscler Suppl Source Type: research

Influence of lipoprotein apheresis on circulating plasma levels of miRNAs in patients with high Lp(a).
Abstract BACKGROUND: Lipoprotein apheresis (LA) is a well-established therapy for lowering lipid levels in serious cases of dyslipidaemia, including high levels of lipoprotein(a) [Lp(a)]. This method lowers both LDL cholesterol and Lp(a) by more than 60% in most of patients; however, because randomized clinical studies could be extremely difficult, also other markers of the effect of this procedures on vascular health are of importance. Therefore, in addition to changes in plasma lipids and Lp(a) during LA, we also analysed the response of biomarkers associated with vascular integrity: small non-coding microRNAs (...
Source: Atherosclerosis Supplements - December 1, 2019 Category: Cardiology Authors: Dlouha D, Prochazkova I, Eretova Z, Hubacek JA, Parikova A, Pitha J Tags: Atheroscler Suppl Source Type: research

Homozygous familial hypercholesterolaemia in childhood - The first case report in Southeast Europe.
Abstract Homozygous familial hypercholesterolaemia (HoFH) is the rare, severe, but treatable disease characterised by exceedingly high levels of low-density lipoprotein cholesterol (LDL-C) and subsequent premature coronary heart disease. Of note, HoFH detection rate and patient access to healthcare and treatment modalities still differ considerably across EU countries. To our current knowledge, there are still no published reports describing HoFH in the paediatric population of Southeastern Europe. In this case report, a few important topics on obstacles in getting adequate health care service and management of Ho...
Source: Atherosclerosis Supplements - December 1, 2019 Category: Cardiology Authors: Bjelakovic B, Stefanutti C, Pisciotta L, Watts G, Bejiqi R Tags: Atheroscler Suppl Source Type: research

Lipoprotein apheresis - Shortening of treatment intervals reduces cardiovascular events: Case reports.
CONCLUSIONS: The intensified treatment regimen resulted in an improvement in clinical symptoms and no further progression of atherosclerosis. In conclusion, shorter therapeutic Lp-apheresis intervals, at least temporarily, should be considered in patients who suffer from clinical and/or angiographic progression of atherosclerosis, despite maximal lipid lowering medication and weekly Lp-apheresis. PMID: 31818444 [PubMed - in process] (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - December 1, 2019 Category: Cardiology Authors: Berent T, Berent R, Sinzinger H Tags: Atheroscler Suppl Source Type: research

Lipoprotein(a) - Marker for cardiovascular risk and target for lipoprotein apheresis.
s U Abstract Lipoprotein(a) (Lp(a)) consists of an LDL particle whose apolipoprotein B (apoB) is covalently bound to apolipoprotein(a) (apo[a]). An increased Lp(a) concentration is a causal, independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and a predictor of incident or recurrent cardiovascular events. Although Lp(a) was first described as early as 1963, only the more recent results of epidemiological, molecular, and genetic studies have led to this unequivocal conclusion. More than 20% of Western populations have elevated Lp(a) values. Lp(a) concentrations should be always part of the li...
Source: Atherosclerosis Supplements - December 1, 2019 Category: Cardiology Authors: Klingel R, Heigl F, Schettler V, Roeseler E, Grützmacher P, Hohenstein B, Vogt A, Fassbender C, Heibges A, Julius U Tags: Atheroscler Suppl Source Type: research

Lipoprotein apheresis in Germany - Still more commonly indicated than implemented. How can patients in need access therapy?
CONCLUSIONS: Incidence and prevalence of LA patients in our region demonstrate that based on our ongoing patient-centered approach the access of patients in need to LA is substantially above the German average, thus contributing to an extraordinary reduction of cardiovascular events in the population we in particular feel responsible for. PMID: 31818446 [PubMed - in process] (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - December 1, 2019 Category: Cardiology Authors: Heigl F, Pflederer T, Klingel R, Hettich R, Lotz N, Reeg H, Schettler VJJ, Roeseler E, Grützmacher P, Hohenstein B, Julius U Tags: Atheroscler Suppl Source Type: research

Short- and long-term effects of lipoprotein apheresis on plasma hormones in patients with therapy-resistant dyslipidemia.
CONCLUSIONS: In summary, these data suggest that although different LA techniques considerably differ in their acute effects on hormone levels during LA, they did not alter long-term hormone levels sustainably. PMID: 31818447 [PubMed - in process] (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - December 1, 2019 Category: Cardiology Authors: Walther R, Julius U, Tselmin S, Schatz U, Bornstein SR, Graessler J Tags: Atheroscler Suppl Source Type: research

Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis.
CONCLUSIONS: 3/4 of LA patients could not stop extracorporeal treatment after PCSK9i administration. In hypercholesterolemic patients with coexisting elevated Lp(a) and progressive cardiovascular disease the combination of LA and PCSK9i could be beneficial. The total patients' number in LA units increases due to persons with Lp(a)-hyperlipoproteinemia. PMID: 31818448 [PubMed - in process] (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - December 1, 2019 Category: Cardiology Authors: Tselmin S, Julius U, Weinert N, Bornstein SR, Schatz U Tags: Atheroscler Suppl Source Type: research

One year follow-up of patients with reduced left ventricular ejection fraction (LVEF) on lipoprotein apheresis.
We examined 18 patients before initiation and after one year of ongoing LP-apheresis. 13 patients (11 males, 2 females, mean age 58.3 ± 5.3 years, groups A) were since more than a year on stable, unchanged statin treatment (atorvastatin 40 mg, simvastatin 40 mg, rosuvastatin 20 mg±ezetimibe), the other 5 patients (3 males, 2 females, mean age 57.1 ± 4.6 years, group B) were intolerant to statins being on micronized fenofibrate±resorption inhibitors (cholestyramine). All patients had a Lp(a) 
Source: Atherosclerosis Supplements - December 1, 2019 Category: Cardiology Authors: Giurgea GA, Karkutli E, Granegger S, Berent R, Derfler K, Sinzinger H Tags: Atheroscler Suppl Source Type: research

Optical coherence tomography of retinal and choroidal layers in patients with familial hypercholesterolaemia treated with lipoprotein apheresis.
Abstract PURPOSE: Detect and quantify morpho-functional alterations of the retina and choroid in patients affected by familial hypercholesterolemia (FH) treated with lipoprotein apheresis (LA) using optic coherence tomography (OCT) and optic coherence tomography-angriography (OCTA). DESIGN: Observational study. SUBJECTS: To be diagnosed: A group of 20 patients (40 eyes) being clinically and genetically diagnosed as FH and under treatment (FH-Group)", for at least 2 years, was compared to a control group of 20 healthy subjects (40 eyes), with a normal lipid profile and no ocular disease (CT-Group). ...
Source: Atherosclerosis Supplements - December 1, 2019 Category: Cardiology Authors: Stefanutti C, Mesce D, Pacella F, Di Giacomo S, Turchetti P, Forastiere M, Trovato Battagliola E, La Torre G, Smaldone G, Pacella E Tags: Atheroscler Suppl Source Type: research

Apheresis as emerging treatment option in severe early onset preeclampsia.
r K Abstract Based on an early suggestion by Winkler et al. 2003 and a subsequent successful study by Wang et al. 2006 using lipid apheresis (LA) in 9 patients with preeclampsia to prolong pregnancies, the use of apheresis as therapeutic option in severe early onset preeclampsia has received increasing attention. Further studies using different LA systems also prolonged pregnancy and have been published in the last few years. Albeit using different LA systems and relying on different working hypothesis, all studies demonstrated a promising stabilisation against the disease's progression. Overall time fro...
Source: Atherosclerosis Supplements - December 1, 2019 Category: Cardiology Authors: Contini C, Pütz G, Pecks U, Winkler K Tags: Atheroscler Suppl Source Type: research

Efficiency and problems of statin therapy in patients with heterozygous familial hypercholesterolemia.
Abstract Familial hypercholesterolemia (FH) is associated with a very high risk of cardiovascular complications and the need for an early aggressive lipid-lowering therapy. The achievement of lipid target levels is often an extremely difficult task in these patients. AIMS: to analyze sex and age structure of ischemic heart disease (IHD) in patients with a definite, possible and probable FH. to assess the degree of achievement of low density lipoprotein cholesterol (LDL-C) target levels in FH patients on statin therapy and complications that occur during therapy; to analyze the adherence of FH patients to stat...
Source: Atherosclerosis Supplements - December 1, 2019 Category: Cardiology Authors: Korneva V, Kuznetsova T, Julius U Tags: Atheroscler Suppl Source Type: research

Lipoprotein apheresis in Austria - Reduction of cardiovascular events by regular lipoprotein apheresis treatment.
CONCLUSIONS: The significant reduction in MACE and vascular disease during regular LP-apheresis at weekly intervals is consistent with data from the literature. Difficulties arise in comparing such studies due to different definition of events or interventions and different study durations. However, LP-apheresis is an efficient treatment option and causes significantly prolonged event-free survival for patients at risk. PMID: 31818453 [PubMed - in process] (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - December 1, 2019 Category: Cardiology Authors: Berent T, Derfler K, Berent R, Sinzinger H Tags: Atheroscler Suppl Source Type: research

Serum uric acid and left ventricular geometry pattern in obese children.
Abstract BACKGROUND: Relative importance of traditional and non-traditional components of metabolic syndrome (MetSy) as risk factors for subclinical target organ damage in obese children is still under investigation. Recent studies highlight the role of serum uric acid (SUA) as an emerging non-traditional independent risk factor which correlates with obesity, MetSy, type 2 diabetes, preclinical cardiac and extracardiac organ damage, as well as cardiovascular events. AIMS: To study the relationship between SUA and left ventricular geometry pattern in obese children with or without MetSy. PATIENTS AND METH...
Source: Atherosclerosis Supplements - December 1, 2019 Category: Cardiology Authors: Bjelakovic B, Stefanutti C, Bonic D, Vukovic V, Kavaric N, Saranac L, Kocic G, Klisic A, Jevtović Stojmenov T, Lukic S, Jovic M, Bjelakovic M Tags: Atheroscler Suppl Source Type: research

Cardiovascular risk factors in patients with premature cardiovascular events attending the University of Dresden Lipid Clinic.
CONCLUSION: In patients with premature CV disease male sex, smoking, hypertension, a positive family history and elevated Lp(a) are the most important CV risk factors. Lp(a) should be considered in the management of young patients with CV disease. PMID: 31818455 [PubMed - in process] (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - December 1, 2019 Category: Cardiology Authors: Schatz U, Fischer S, Müller G, Tselmin S, Birkenfeld AL, Julius U, März W, Bornstein SR Tags: Atheroscler Suppl Source Type: research

The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion.
e;k M, Catapano AL PMID: 31451336 [PubMed - as supplied by publisher] (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - August 17, 2019 Category: Cardiology Authors: Banach M, Bruckert E, Descamps OS, Ellegård L, Ezhov M, Föger B, Fras Z, Kovanen PT, Latkovskis G, März W, Panagiotakos DB, Paragh G, Pella D, Pirillo A, Poli A, Reiner Ž, Silbernagel G, Viigimaa M, Vrablík M, Catapano AL Tags: Atheroscler Suppl Source Type: research

Effectiveness of different immunoadsorption columns for anti-A/B antibody depletion.
orath C Abstract OBJECTIVE: In recent studies, semi-selective compared to antigen-specific immunoadsorption (IA) columns showed comparable effectiveness in anti-A/B antibody removal before incompatible living donor kidney transplantation. Semi-selective columns allow a greater number of IA treatments at lower costs. They are also capable of removing potentially harmful human leukocyte antigen alloantibodies. Nevertheless, additional plasma exchange treatments are often necessary to reach the preoperative target titer, most likely due to an inadequate anti-A/B IgM antibody depletion. METHODS: We compared the e...
Source: Atherosclerosis Supplements - August 17, 2019 Category: Cardiology Authors: Speer C, Kälble F, Pego da Silva L, Nusshag C, Schaier M, Becker LE, Klein K, Beimler J, Sommerer C, Leo A, Süsal C, Mehrabi A, Zeier M, Morath C Tags: Atheroscler Suppl Source Type: research

Statin-induced muscular side effects at rest and exercise - An anatomical mapping.
CONCLUSIONS: Physical activity seems to be a key trigger for onset of statin-induced muscular side effects. The appearance of symptoms can be symmetrical, asymmetrical, generalized or in isolated muscle groups only. Different statins usually produce similar symptoms, but often some patients tolerate one statin better than another. PMID: 31447216 [PubMed - as supplied by publisher] (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - August 17, 2019 Category: Cardiology Authors: Berent T, Berent R, Steiner S, Sinzinger H Tags: Atheroscler Suppl Source Type: research

Immunoadsorption in nephrotic syndrome: Where are we now and where are we going from here?
Abstract Idiopathic nephrotic syndrome (INS) is characterized by three different entities, namely minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS) and membranous nephropathy (MN). While there is an increasing understanding of primary MN with the discovery of antibodies directed against phospholipase A2 receptor (PLA2R Ab) and thrombospondin type 1 domain-containing 7A, circulatory factors causative of inducing MCD and FSGS remain in part elusive. Extracorporeal treatment forms (mostly plasma exchange) have been reserved for patients with either a disease course refractory to commonly prescri...
Source: Atherosclerosis Supplements - August 17, 2019 Category: Cardiology Authors: Kronbichler A, Gauckler P, Lee KH, Shin JI, Malvezzi P, Mayer G Tags: Atheroscler Suppl Source Type: research

The frequency of familial hypercholesterolemia amongst patients in the outpatient clinic of the tertiary specialized cardiology center in Kyrgyzstan.
CONCLUSION: Frequency of potential FH (definite and probable) in our analysis was low. To understand the real prevalence of FH in a Kyrgyz population epidemiological study is needed. PMID: 30876526 [PubMed - in process] (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - March 1, 2019 Category: Cardiology Authors: Lunegova OS, Mirrakhimov AE, Hodzhiboboev E, Bektasheva EE, Neronova KV, Toktomamatov UM, Zakirov U, Asanbaev A, Arapova RA, Abilova SS, Kerimkulova AS, Mirrakhimov EM Tags: Atheroscler Suppl Source Type: research

Familial hypercholesterolemia in China half a century: A review of published literature.
CONCLUSIONS: Large-scale epidemiological investigation of FH has not been demonstrated, the recognition of FH remains rudimentary, and the guidelines are incomplete in China. The diagnosis and management of Chinese FH needs to be improved. PMID: 30876527 [PubMed - in process] (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - March 1, 2019 Category: Cardiology Authors: Peng J, Wu X, Wang S, Zhang S, Wang X, Liu Z, Hong J, Ye P, Lin J Tags: Atheroscler Suppl Source Type: research

Percutaneous coronary intervention for a Chinese familial hypercholesterolemia homozygous under the guidance of optical  coherence tomography.
In this study, a Chinese male HoFH received percutaneous coronary intervention for unstable angina. After analyzed his genetic and follow-up data, OCT was performed during interventional therapy. Multiple lipid rich plaques accompanied with inflammatory cell infiltration and a thin-cap fibroatheroma(TCFA) were noted, which reflected the vulnerability of plaques. The utility of OCT had certain guiding significance for strategy of interventional therapy and the long-term drug management. And this case suggested that it was important to undergo OCT examination for patients with HoFH who required percutaneous coronary interven...
Source: Atherosclerosis Supplements - March 1, 2019 Category: Cardiology Authors: Liu Z, Peng J, Wang S, Jiang T, Zhang W, Zhang C, Chen Y, Meng K, Lin J Tags: Atheroscler Suppl Source Type: research

Establishing a familial hypercholesterolaemia register - The first year.
CONCLUSIONS: During this year the register was established and is functional: awareness is being raised. Future steps will target process improvement for effectiveness and sustainability. PMID: 30876529 [PubMed - in process] (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - March 1, 2019 Category: Cardiology Authors: Tilney M Tags: Atheroscler Suppl Source Type: research

Variable expression and penetrance in Portuguese families with Familial Hypercholesterolemia with mild phenotype.
Abstract Familial hypercholesterolemia is an Mendelian dominant disorder characterized by defects of the low density lipoprotein receptor (LDLR) that result in a defective removal of LDL from plasma, which promotes deposition of cholesterol in the skin (xanthelasma), tendons (xanthomas), and arteries (atherosclerosis). Diagnosis severe clinical phenotype FH with Dutch Lipid Clinic Network Criteria, encompassing history of premature ASCVD, tendon xanthomas, and a family history of hypercholesterolemia and premature ASCVD in relatives is rare in the Portuguese FH patients. There is a variability of the phenotype in ...
Source: Atherosclerosis Supplements - March 1, 2019 Category: Cardiology Authors: Gaspar IM, Gaspar A Tags: Atheroscler Suppl Source Type: research

Investigating the association between familial hypercholesterolemia and perceived depression.
CONCLUSIONS: Patients with clinical phenotype of FH are associated with subjectively perceived depression, particularly among FH patients with a family history of CHD. PMID: 30876531 [PubMed - in process] (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - March 1, 2019 Category: Cardiology Authors: Chang NT, Su TC Tags: Atheroscler Suppl Source Type: research

Achilles tendon ultrasonography - A useful screening tool for cardiovascular risk estimation in patients with severe hypercholesterolemia.
elskienė I Abstract BACKGROUND AND AIMS: Achilles tendon lesions have long been associated with genetic defects in lipid metabolism and increased risk of cardiovascular diseases (CVD). With this study we aimed to evaluate the usefulness of Achilles tendon ultrasonography in identifying people at greater risk among subjects with severe hypercholesterolemia (SH) in a high-risk population. METHODS: During the period of 2016-2017 a total of 213 participants were enrolled in this case-control study. Data of 110 patients with SH and 103 age and sex matched controls without dyslipidaeplemia and established CVD was ...
Source: Atherosclerosis Supplements - March 1, 2019 Category: Cardiology Authors: Kutkienė S, Petrulionienė Ž, Laucevičius A, Čerkauskienė R, Samuilis A, Augaitienė V, Gedminaitė A, Bieliauskienė G, Šaulytė-Mikulskienė A, Staigytė J, Petrulionytė E, Gargalskaitė U, Skiauterytė E, Matuzevičienė G, Kovaitė M, Nedzelski Tags: Atheroscler Suppl Source Type: research

Epidemiology of cardiovascular risk factors in two population-based studies.
Abstract We aimed to compare cardiovascular risk factors prevalence in Italy and Russia through cross-sectional database analysis. The study has been based on data from ESSE-RF and from baseline of PLIC study, two population-based epidemiological studies aimed to investigate prevalence of risk factors and evaluating contribution of traditional and new risk factors into morbidity and cardiovascular mortality. A total of 2203 patients with left and right intima-media thickness (IMT) measurements constituted the source population (1205 from PLIC study and 998 from ESSE-RF study). Sample of ESSE-RF study had slightly ...
Source: Atherosclerosis Supplements - August 25, 2018 Category: Cardiology Authors: Olmastroni E, Shlyakhto EV, Konradi AO, Rotar OP, Alieva AS, Boyarinova MA, Baragetti A, Grigore L, Pellegatta F, Tragni E, Catapano AL, Casula M Tags: Atheroscler Suppl Source Type: research

Notch, BMP and WNT/ β-catenin network is impaired in endothelial cells of the patients with thoracic aortic aneurysm.
In conclusion endothelial cells of the patients with thoracic aortic aneurysm have dysregulated Notch, BMP and WNT/β-catenin related signaling. Shear stress-response and cross-talk between Notch and Wnt pathways that normally ensures aortic integrity and resistance of endothelial cells to stress is impaired in aneurysmal patients. PMID: 30172576 [PubMed - as supplied by publisher] (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - August 25, 2018 Category: Cardiology Authors: Kostina A, Bjork H, Ignatieva E, Irtyuga O, Uspensky V, Semenova D, Maleki S, Tomilin A, Moiseeva O, Franco-Cereceda A, Gordeev M, Faggian G, Kostareva A, Eriksson P, Malashicheva A Tags: Atheroscler Suppl Source Type: research

Standardization of laboratory and lipid profile evaluation: A call for action with a special focus in 2016 ESC/EAS dyslipidaemia guidelines - Full report.
Abstract Even with the improvement in lifestyle interventions, a better control of cardiovascular (CV) risk factors, and improvements in CV outcomes, cardiovascular disease (CVD) still persists as the leading cause of morbidity and mortality in Portugal and Europe. Atherogenic dyslipidaemias, namely hypercholesterolaemia, have a crucial and causal role in the development of atherosclerotic CVD. The clinical approach of a patient with dyslipidaemia involves a watchful diagnosis, sustained in lipid and lipoprotein laboratory procedures, which must be harmonized and standardized. Standardization of lipid test results...
Source: Atherosclerosis Supplements - June 1, 2018 Category: Cardiology Authors: da Silva PM, Duarte JS, von Hafe P, Gil V, de Oliveira JN, de Sousa G Tags: Atheroscler Suppl Source Type: research

Corrigendum to "Monascus purpureus for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: A clinical study" [Atherosclerosis (Supplements) 30C (2017) 86-91].
Corrigendum to "Monascus purpureus for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: A clinical study" [Atherosclerosis (Supplements) 30C (2017) 86-91]. Atheroscler Suppl. 2017 Nov 16;: Authors: Stefanutti C, Mazza F, Mesce D, Morozzi C, Di Giacomo S, Vitale M, Pergolini M PMID: 29153764 [PubMed - as supplied by publisher] (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - November 16, 2017 Category: Cardiology Authors: Stefanutti C, Mazza F, Mesce D, Morozzi C, Di Giacomo S, Vitale M, Pergolini M Tags: Atheroscler Suppl Source Type: research

History of lipidology and lipoprotein apheresis.
Abstract This review tells the story of atherosclerosis research in the beginning of the 20th century. It presents the significance of cardiovascular diseases and addresses major questions currently being discussed among lipidologists and the current thinking with respect to low LDL-cholesterol levels and HDL. It provides an overview of the period during which lipid-modifying drugs were introduced and their relevance with respect to cardiovascular outcome data and lists possible reasons why some patients develop new cardiovascular events while being treated with statins. Especially impressive is the history of the...
Source: Atherosclerosis Supplements - November 1, 2017 Category: Cardiology Authors: Julius U Tags: Atheroscler Suppl Source Type: research

Lipoprotein apheresis influences monocyte subpopulations.
Abstract BACKGROUND: Monocytes can be differentiated into subpopulations depending on their expression profile of CD14 and CD16. CD16-positive monocytes are associated with coronary artery disease. Up to now, no data exist about the effect of lipoprotein apheresis (LA) on the distribution of monocyte subpopulations. METHODS: 80 patients who underwent LA at the University Hospital Dresden were included in the study. 8 out of the 80 LA patients received LA for the first time at the time point of blood analysis. Six different methods of LA were used (H.E.L.P. n = 8; Liposorber D n = 10; LF n&...
Source: Atherosclerosis Supplements - November 1, 2017 Category: Cardiology Authors: Jellinghaus S, Reich C, Schatz U, Tselmin S, Ibrahim K, Pfluecke C, Schauer A, Bornstein SR, Hohenstein B, Strasser RH, Julius U, Poitz DM Tags: Atheroscler Suppl Source Type: research

Long-term follow-up of circulating oxidative stress markers in patients undergoing lipoprotein apheresis by Direct Adsorption of Lipids (DALI).
CONCLUSION: DALI apheresis repeatedly decreases atherogenic lipid/lipoprotein profile and oxidative stress biomarker levels during each session. Among all investigated parameters no longitudinal effects over two years could be observed. PMID: 29096826 [PubMed - in process] (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - November 1, 2017 Category: Cardiology Authors: Kopprasch S, Bornstein SR, Bergmann S, Graessler J, Hohenstein B, Julius U Tags: Atheroscler Suppl Source Type: research

Pleiotropic effects of regular lipoprotein-apheresis.
DISCUSSION: These findings indicate that beyond the well known lipid/lipoprotein lowering action the broad spectrum of functional tests examined reflecting mainly endothelial function is significantly improved by LP-apheresis treatment on the long-term and seems to be a key underlying reason for the clinical improvement seen in these patients. PMID: 29096827 [PubMed - in process] (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - November 1, 2017 Category: Cardiology Authors: Sinzinger H, Steiner S, Derfler K Tags: Atheroscler Suppl Source Type: research

Analysis of circulating miRNAs in patients with familial hypercholesterolaemia treated by LDL/Lp(a) apheresis.
Abstract BACKGROUND: LDL/Lp(a) apheresis therapy is a well-established method of aggressively lowering LDL and Lp(a). Recently, miRNAs have been discussed as markers of vascular status including atherosclerosis. MiRNAs inhibit post-transcriptional processes through RNA duplex formation resulting in gene silencing or regulation of gene expression. MATERIALS AND METHODS: We measured a profile of 175 plasma-circulating miRNAs using pre-defined Serum/Plasma Focus Human microRNA PCR Panels in pooled samples of 11 subjects with familial hypercholesterolaemia under long-term apheresis treatment. Subsequently we anal...
Source: Atherosclerosis Supplements - November 1, 2017 Category: Cardiology Authors: Dlouha D, Blaha M, Blaha V, Fatorova I, Hubacek JA, Stavek P, Lanska V, Parikova A, Pitha J Tags: Atheroscler Suppl Source Type: research

LDL apheresis improves coronary flow reserve on the left anterior descending artery in patients with familial hypercholesterolemia and chronic ischemic heart disease.
Abstract BACKGROUND: LDL apheresis (LA) influences the microcirculation, endothelial function and cardiovascular homeostasis. The aim of our study was to analyze temporal variations of coronary flow reserve (CFR) on the left anterior descending artery, obtained during dipyridamole stress echocardiography (DSE), in patients with severe familial hypercholesterolemia on LA (LA group) or not (not LA group) and ischemic heart disease (IHD). METHODS: The LA group consisted in 10 patients (mean age 65 ± 7 years, male 70%) with Familial Hypercholesterolemia and chronic IHD on maximally tolerated lipi...
Source: Atherosclerosis Supplements - November 1, 2017 Category: Cardiology Authors: Sampietro T, Sbrana F, Pasanisi EM, Bigazzi F, Petersen C, Coceani M, Dal Pino B, Ripoli A, Pianelli M, Luciani R Tags: Atheroscler Suppl Source Type: research

Serum of patients with antiphospholipid syndrome induces adhesion molecules in endothelial cells.
CONCLUSION: An augmented expression of endothelial adhesion molecules is involved in the pathophysiology of patients with antiphospholipid syndrome. PMID: 29096830 [PubMed - in process] (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - November 1, 2017 Category: Cardiology Authors: Engel B, Müller G, Roch B, Schröder HE, Aringer M, Bornstein SR, Morawietz H Tags: Atheroscler Suppl Source Type: research

Endothelial function and gene expression in perivascular adipose tissue from internal mammary arteries of obese patients with coronary artery disease.
CONCLUSION: Our data suggest a partially reduced endothelial function in internal mammary arteries of adipose patients with a BMI between 25 and 30 kg/m(2) undergoing coronary artery bypass grafting surgery. Increased adiponectin expression in perivascular tissue might contribute to maintenance of endothelial function in obese patients with a BMI above 30 kg/m(2). PMID: 29096831 [PubMed - in process] (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - November 1, 2017 Category: Cardiology Authors: Cybularz M, Langbein H, Zatschler B, Brunssen C, Deussen A, Matschke K, Morawietz H Tags: Atheroscler Suppl Source Type: research

Antioxidant defense system in familial hypercholesterolemia and the effects of lipoprotein apheresis.
acute;k Z, Žák P, Sobotka L Abstract Oxidative stress is thought to play an important role in the pathogenesis of disorders associated with atherosclerosis. Alpha-tocopherol is considered to be an effective lipophilic antioxidant, which protects lipid membranes against peroxidation and thus prevents cell damage by reaction with free radicals. However, measurement of alpha-tocopherol concentration in serum does not reflect the content of α-tocopherol in membranes whereas erythrocyte alpha-tocopherol may be good indicator of antioxidative status. Therefore a simple isocratic reversed phase HPLC method ...
Source: Atherosclerosis Supplements - November 1, 2017 Category: Cardiology Authors: Blaha V, Blaha M, Solichová D, Krčmová LK, Lánská M, Havel E, Vyroubal P, Zadák Z, Žák P, Sobotka L Tags: Atheroscler Suppl Source Type: research

Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity.
Abstract BACKGROUND: An elevated lipoprotein(a) (Lp(a)) level is observed in more than 30% of patients with stable ischemic heart disease (SIHD). We conducted an investigation of the effects of specific Lp(a) apheresis on the progression of atherosclerosis in SIHD patients with Lp(a) levels greater than 50 mg/dL. METHODS: We prospectively enrolled 15 patients diagnosed with SIHD based on symptom-driven coronary angiography findings, with Lp(a) ≥50 mg/dL and a low density lipoprotein cholesterol (LDL-C) ≤2.5 mmol/L, who were on long-term statin therapy. They underwent weekly Lp(a) apheresi...
Source: Atherosclerosis Supplements - November 1, 2017 Category: Cardiology Authors: Pokrovsky SN, Afanasieva OI, Safarova MS, Balakhonova TV, Matchin YG, Adamova IYU, Konovalov GA, Ezhov MV Tags: Atheroscler Suppl Source Type: research

Lipoprotein apheresis in patients with peripheral artery disease and lipoprotein(a)-hyperlipoproteinemia: 2-year follow-up of a prospective single center study.
Abstract OBJECTIVE: Elevated plasma levels of lipoprotein(a) [Lp(a)], referred to as lipoprotein(a)-hyperlipoproteinemia [Lp(a)-HLP], are an independent risk factor for atherosclerosis. Lipoprotein apheresis (LA) enables an effective reduction of Lp(a) plasma levels. The present study investigates the effects of LA in patients with Lp(a)-HLP and peripheral artery disease (PAD). METHODS: Ten patients with isolated Lp(a)-HLP and severe PAD and who had recently undergone a revascularization (index procedure) were prospectively included in this observational single center study. All patients received weekly LA. A...
Source: Atherosclerosis Supplements - November 1, 2017 Category: Cardiology Authors: Poller WC, Berger A, Dreger H, Morgera S, Enke-Melzer K Tags: Atheroscler Suppl Source Type: research

Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.
CONCLUSION: The MultiSELECt trial provides the unique opportunity to demonstrate the efficiency of LA on CVD in patients with elevated Lp(a) under strongly controlled conditions. PMID: 29096835 [PubMed - in process] (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - November 1, 2017 Category: Cardiology Authors: Hohenstein B, Julius U, Lansberg P, Jaeger B, Mellwig KP, Weiss N, Graehlert X, Roeder I, Ramlow W Tags: Atheroscler Suppl Source Type: research

Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis.
This study was performed in patients after successful CABG and consisted of three parts: a) a retrospective part with computed tomography assessment of vein graft patency in patients with first-year recurrence of chest pain after CABG (n = 102); b) a prospective trial with evaluation of cardiovascular outcomes during follow up time up to 15 years in relation to baseline Lp(a) levels (n = 356); c) an 12-months interventional controlled study in 50 patients with low-density lipoprotein cholesterol (LDL-C) levels>2.6 mmol/L prior to the operation despite statin treatment that allocated into 2 group...
Source: Atherosclerosis Supplements - November 1, 2017 Category: Cardiology Authors: Ezhov MV, Afanasieva OI, Il'ina LN, Safarova MS, Adamova IY, Matchin YG, Konovalov GA, Akchurin RS, Pokrovsky SN Tags: Atheroscler Suppl Source Type: research

The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.
Abstract Increased triglyceride levels (higher than ∼1000 mg/dL) are associated with an increased risk for pancreatitis. Apolipoprotein-CIII (apo-CIII) plays a key role in the metabolism of triglycerides and triglyceride-rich lipoproteins. While loss of function mutations in the gene encoding apo-CIII (APOC3) are associated with low triglyceride levels and a decreased risk for cardiovascular disease (CVD), overexpression of APOC3 is associated with hypertriglyceridemia. Although many drugs such as fibrates, statins and omega-3 fatty acids modestly decrease triglyceride levels (and apo-CIII concentrations)...
Source: Atherosclerosis Supplements - November 1, 2017 Category: Cardiology Authors: Gouni-Berthold I Tags: Atheroscler Suppl Source Type: research

Effect of different lipid apheresis methods on plasma polyunsaturated fatty acids.
KH Abstract Lipoprotein apheresis has been shown to improve the cardiovascular outcome in patients with atherosclerotic disease and therapy-refractory hypercholesterolemia or elevated lipoprotein (a) (Lp(a)). An elevated intake of omega-3 polyunsaturated fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) has also been associated with a reduced cardiovascular risk. However, until now only little is known about the effect of apheresis treatment on the levels of omega-6 and omega-3 polyunsaturated fatty acids (n-6 PUFA and n-3 PUFA) in patients. Using gas chromatography (GC) the present s...
Source: Atherosclerosis Supplements - November 1, 2017 Category: Cardiology Authors: Schmöcker C, Kassner U, Ostermann AI, Kiesler S, Steinhagen-Thiessen E, Schebb NH, Weylandt KH Tags: Atheroscler Suppl Source Type: research

Lipoprotein apheresis downregulates IL-1 α, IL-6 and TNF-α mRNA expression in severe dyslipidaemia.
Lipoprotein apheresis downregulates IL-1α, IL-6 and TNF-α mRNA expression in severe dyslipidaemia. Atheroscler Suppl. 2017 Nov;30:200-208 Authors: Stefanutti C, Mazza F, Pasqualetti D, Di Giacomo S, Watts GF, Massari MS, de Neve J, Morozzi C, Fischer M Abstract BACKGROUND AND AIMS: Dyslipidaemias are associated with cardiovascular mortality and morbidity, driven by unstable atherosclerotic plaques with inflammatory infiltrates. Levels of messenger RNA (mRNA) for pro-inflammatory cytokines have been positively correlated with atherosclerotic disease progression. Therapeutic lipoprotein aphe...
Source: Atherosclerosis Supplements - November 1, 2017 Category: Cardiology Authors: Stefanutti C, Mazza F, Pasqualetti D, Di Giacomo S, Watts GF, Massari MS, de Neve J, Morozzi C, Fischer M Tags: Atheroscler Suppl Source Type: research